97 related articles for article (PubMed ID: 16538101)
21. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
22. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
[TBL] [Abstract][Full Text] [Related]
23. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
24. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
[TBL] [Abstract][Full Text] [Related]
26. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
27. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
Ancel D; Amiot X; Chaslin-Ferbus D; Hagege I; Garioud A; Girot R; Pol S; Grange JD
Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):726-9. PubMed ID: 19404206
[TBL] [Abstract][Full Text] [Related]
28. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
[TBL] [Abstract][Full Text] [Related]
29. Individualisation of antiviral therapy for chronic hepatitis C.
Teoh NC; Farrell GC; Chan HL
J Gastroenterol Hepatol; 2010 Jul; 25(7):1206-16. PubMed ID: 20594246
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
Iyoda K; Kato M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):502-5. PubMed ID: 15359850
[No Abstract] [Full Text] [Related]
31. Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting.
Cooper C
Clin Infect Dis; 2012 Aug; 55(3):418-25. PubMed ID: 22491342
[TBL] [Abstract][Full Text] [Related]
32. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].
Cornberg M; Hüppe D; Wiegand J; Felten G; Wedemeyer H; Manns MP
Z Gastroenterol; 2003 Jun; 41(6):517-22. PubMed ID: 12806536
[TBL] [Abstract][Full Text] [Related]
34. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
35. [Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
Fukuda A
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):493-6. PubMed ID: 15359848
[No Abstract] [Full Text] [Related]
36. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876
[TBL] [Abstract][Full Text] [Related]
37. Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
Kohjima M; Enjoji M; Yoshimoto T; Yada R; Fujino T; Aoyagi Y; Fukushima N; Fukuizumi K; Harada N; Yada M; Kato M; Kotoh K; Nakashima M; Sakamoto N; Tanaka Y; Nakamuta M
J Med Virol; 2013 Feb; 85(2):250-60. PubMed ID: 23161429
[TBL] [Abstract][Full Text] [Related]
38. [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].
Doffoël-Hantz V; Loustaud-Ratti V; Ramos-Casals M; Alain S; Bezanahary H; Liozon E; Fauchais AL; Vidal E
Rev Med Interne; 2005 Feb; 26(2):88-94. PubMed ID: 15710254
[TBL] [Abstract][Full Text] [Related]
39. High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.
Lindahl K; Hörnfeld E; Ståhle L; Carlsson T; Weiland O; Parke Å; Schvarcz R
Ther Drug Monit; 2015 Dec; 37(6):745-50. PubMed ID: 25811342
[TBL] [Abstract][Full Text] [Related]
40. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
